Tx Selection and Optimization in MCL

CME

Treatment Selection and Optimization in MCL From a European Union Perspective

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 15, 2025

Expiration: October 14, 2025

Activity

Progress
1 2
Course Completed

References

  1. Yoon DH, Cao J, Chen TY, et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol. 2020;13:21.
  2. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62-iv71.
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v.2.2025. nccn.org. Accessed April 7, 2025.
  4. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
  5. Ibrutinib [prescribing information]. Sunnyvale, CA: Pharmacyclics LLC; 2024.
  6. Acalabrutinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  7. Zanubrutinib [prescribing information]. San Mateo, CA: BeiGene USA, Inc; 2025.
  8. Ibrutinib [prescribing information]. Beerse, Belgium: Janssen-Cilag International NV; 2022.
  9. Acalabrutinib [prescribing information]. Cambridge, United Kingdom: AstraZeneca AB; 2025.
  10. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659-667.
  11. Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase. Clin Cancer Res. 2020;26:4216-4224.
  12. Berglof A, Hamasy A, Meinke S, et al. Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 2015;82:208-217.
  13. Moore DC, Thompson D. A review of the Bruton tyrosine kinase inhibitors in B-cell malignancies. J Adv Pract Oncol. 2021;12:439-447.
  14. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298-1307.
  15. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988-3997.
  16. Dreyling M, Doorduijn JK, Gine E, et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL Network. Presented at: American Society of Hematology Annual Meeting and Exposition; 2024. Abstr 240.
  17. Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:2482-2494.
  18. Wang M, Mayer J, Belada D, et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial. Presented at: The European Hematology Association Hybrid Congress; 2024. Abstr LB3439.
  19. Dreyling M, Tam CS, Wang M, et al. A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17:255-262.
  20. Lewis DJ, Jerkeman M, Sorrell L, et al. Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, Enrich. Presented at: American Society of Hematology Annual Meeting and Exposition; 2024. Abstr 235.
  21. Kumar A, Soumerai J, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025;145:497-507.
  22. Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137:877-887.
  23. Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200-213.
  24. Ran F, Liu Y, Wang C, et al. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem. 2022;229:114009.
  25. Pirtobrutinib [prescribing information]. Utrecht, Netherlands: Eli Lilly Nederland B.V.; 2021.
  26. Brexucabtagene autoleucel [prescribing information]. Hoofddorp, Netherlands: Kite Pharma EU B.V.; 2019.
  27. Shah NN, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment. Presented at: American Society of Clinical Oncology Annual Meeting; 2023. Abstr 7514.
  28. Shah NN, Wang M, Roeker LE, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025;110:92-102.
  29. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331-1342.
  30. Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023a;41:555-567.
  31. Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US lymphoma CAR T consortium. J Clin Oncol. 2023b;41:2594-2606.
  32. Tapia-Galisteo A, Alvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16:83.
  33. Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study. J Clin Oncol. 2025;43:318-328.